Table 3.
| Loratadine Dissatisfied Segments – Severe Allergic Rhinitis | ||
| Converted to Fexofenadine N = 88 (weighted) | Converted to Desloratadine N = 35 (weighted) | |
| Side Effects | ||
| Sum of Adverse Events1 | 2.0** | 1.35** |
| Symptom Relief | ||
| EOD Failure – Nighttime Awakening1 | 2.93** | 1.81** |
| EOD Failure – Morning Symptoms1 | 3.74 | 3.62 |
| Onset of Relief2 | 4.34 | 4.58 |
| Coverage Period2 | 4.37** | 5.15** |
| Overall Symptom Relief2 | 4.92 | 5.34 |
| Overall Satisfaction | ||
| Continuation Intentions2 | 5.10 | 5.41 |
| Likelihood to Recommend2 | 4.66 | 5.32 |
| Overall Satisfaction with Current Rx2 | 4.67* | 5.37* |
| Satisfaction with Rx Change2 | 4.76 | 5.27 |
*p < = .05 **p < = .01 1 Higher number reflects negative medication experience. 2 Higher number reflects positive medication experience.